Leerink Partners Has Lowered Expectations for Cytokinetics (NASDAQ:CYTK) Stock Price

Key Points

• Leerink Partners cut Cytokinetics’ price target from $103 to $100 but maintained an “outperform” rating, implying about 81% upside from the stock’s then-current price. Analysts’ consensus rating was “Moderate Buy,” with a $106.33 average target.
• Shares fell 13% to $55.36 on Thursday, near their 52-week low. The company nevertheless beat quarterly estimates, reporting a loss of $1.37 per share versus the expected $1.43 loss and revenue of $47.56 million versus $41.88 million expected.
• Cytokinetics remains loss-making, and company insiders sold about 181,000 shares worth $12.5 million over the prior 90 days; the reported sales were made under pre-arranged trading plans.

Cytokinetics (NASDAQ:CYTK - Get Free Report) had its price target decreased by investment analysts at Leerink Partners from $103.00 to $100.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an "outperform" rating on the biopharmaceutical company's stock. Leerink Partners's price target indicates a potential upside of 80.64% from the stock's current price.

CYTK has been the subject of several other reports. Citigroup restated a "market outperform" rating on shares of Cytokinetics in a report on Friday, August 7th. UBS Group reiterated a "buy" rating and set a $104.00 price target on shares of Cytokinetics in a report on Wednesday, October 14th. HC Wainwright reissued a "buy" rating and set a $140.00 price target on shares of Cytokinetics in a research report on Monday, October 19th. William Blair started coverage on shares of Cytokinetics in a report on Friday, October 16th. They issued an "outperform" rating for the company. Finally, Morgan Stanley upgraded shares of Cytokinetics from an "overweight" rating to a "buy" rating in a research report on Tuesday, September 1st. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $106.33.

Cytokinetics Stock Down 13.0%

CYTK traded down $8.24 during trading on Thursday, reaching $55.36. The company's stock had a trading volume of 4,345,430 shares, compared to its average volume of 2,102,162. The firm has a fifty day simple moving average of $66.63 and a two-hundred day simple moving average of $70.05. Cytokinetics has a 1 year low of $54.30 and a 1 year high of $88.31. The company has a market cap of $6.89 billion, a price-to-earnings ratio of -7.64 and a beta of 0.45.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.43) by $0.06. The company had revenue of $47.56 million during the quarter, compared to analysts' expectations of $41.88 million. During the same quarter last year, the company earned ($2.55) earnings per share. Cytokinetics's revenue for the quarter was up 2356.5% on a year-over-year basis. As a group, equities analysts forecast that Cytokinetics will post -5.97 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Fady Malik sold 3,500 shares of the firm's stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $68.29, for a total transaction of $239,015.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares of the company's stock, valued at approximately $10,509,967.58. This trade represents a 2.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 97,926 shares of the business's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total transaction of $6,789,209.58. Following the completion of the sale, the chief executive officer owned 385,320 shares in the company, valued at approximately $26,714,235.60. This trade represents a 20.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 180,926 shares of company stock worth $12,510,340. Company insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On Cytokinetics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC purchased a new stake in Cytokinetics during the 2nd quarter worth about $36,000. Physician Wealth Advisors Inc. raised its position in Cytokinetics by 810.2% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 397 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Cytokinetics by 71.5% in the 3rd quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 191 shares during the period. Rockefeller Capital Management L.P. boosted its stake in shares of Cytokinetics by 842.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 641 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 573 shares during the period. Finally, Manchester Capital Management LLC acquired a new position in shares of Cytokinetics during the third quarter worth about $43,000.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: For Q3 2026, Cytokinetics reported a loss of $1.37 per share, narrower than the $1.43 consensus loss, while revenue of $47.56 million topped estimates of $41.88 million. Revenue was up sharply year over year, and the loss narrowed from $2.55 per share a year earlier. Cytokinetics Q3 Loss Narrows, Revenue Rises
• Positive Sentiment: A valuation commentary argued CYTK could be 41% undervalued, citing the strong quarter and aficamten data. That is an analyst-style valuation view, not a guarantee of future performance. Cytokinetics Could Be 41% Undervalued
• Neutral Sentiment: MYQORZO adoption is a key commercial factor for investors to watch; its uptake could affect Cytokinetics’ future revenue, but the article’s headline does not provide specific sales or adoption figures. How MYQORZO Adoption Will Impact Cytokinetics Stock
• Negative Sentiment: The company remains loss-making despite beating estimates, leaving investors focused on whether product growth can translate into improved profitability. Cytokinetics Q3 Results

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.